Exelixis (EXEL) Operating Income (2010 - 2026)
Exelixis (EXEL) posted quarterly Operating Income of $251.3 million for Q2 2026, up 34.51% year-over-year from $186.9 million in Q2 2025, and up 6.86% quarter-over-quarter from $235.2 million in Q1 2026.
Exelixis (EXEL) Operating Income (2010 - 2026) Analysis & Trends
Exelixis' Operating Income history runs 17 years deep, the most recent figure standing at $251.3 million for Q2 2026.
- In Q2 2026, Operating Income rose 34.51% year-over-year to $251.3 million; the TTM figure through Apr 2026 stood at $936.7 million (up 22.92% YoY), while the FY2026 annual figure was $872.2 million, up 44.26% from the prior year.
- Operating Income for Q2 2026 stood at $251.3 million, up from $235.2 million in the prior quarter.
- The five-year high for Operating Income was $275.9 million in Q2 2024, with the low at -$48.1 million in Q4 2022.
- The 5-year median for Operating Income is $83.7 million (2022), against an average of $123.6 million.
- The sharpest annual moves came in 2022 and 2023: Operating Income soared 1906.88% in 2022, then slumped 121.28% in 2023.
- Exelixis' Operating Income stood at -$48.1 million in 2022, then surged by 270.12% to $81.8 million in 2023, then jumped by 66.38% to $136.1 million in 2024, then surged by 73.83% to $236.5 million in 2025, then grew by 6.26% to $251.3 million in 2026.
- Business Quant data shows EXEL's Operating Income at $251.3 million in Q2 2026, $235.2 million in Q1 2026, and $236.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 248.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 248.41 Mn |
| Apr 3, 2026 | 251.34 Mn |
| Jan 2, 2026 | 235.22 Mn |
| Oct 3, 2025 | 236.54 Mn |
| Jul 4, 2025 | 213.58 Mn |
| Apr 4, 2025 | 186.86 Mn |
| Jan 3, 2025 | 163.21 Mn |
| Sep 27, 2024 | 136.08 Mn |
| Jun 28, 2024 | 275.87 Mn |
| Mar 29, 2024 | 29.46 Mn |
| Dec 29, 2023 | 81.79 Mn |
| Sep 29, 2023 | -17.58 Mn |
| Jun 30, 2023 | 77.85 Mn |
| Mar 31, 2023 | 28.83 Mn |
| Dec 30, 2022 | -48.08 Mn |
| Sep 30, 2022 | 82.61 Mn |
| Jul 1, 2022 | 83.71 Mn |
| Apr 1, 2022 | 83.24 Mn |
| Oct 1, 2021 | 51.62 Mn |
| Jul 2, 2021 | 123.01 Mn |